Chemgenex's flagship drug Ceflatonin, will be swamped by better...

Chemgenex's flagship drug Ceflatonin, will be swamped by better funded, better connected competitors that are doing larger scale testing of the same drug.

Two years ago the co. by this time, expected it would have completed testing. Progress was blocked. It is likely that other equivalents will beat it too market, probably the underlying goal of the powers that be.

CXS should accept that regulators and power players have decided that Ceflatonin's target market has been allocated away from them now. CXS needs to swallow this and refocus its resources.


http://www.dddmag.com/ShowPR.aspx?PUBCODE=016&ACCT=1600000100&ISSUE=0505&RELTYPE=RLSN&PRODCODE=00000000&PRODLETT=T